Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of Directors as it advances towards clinical-stage activities

"We are delighted to welcome Jarl Ulf Jungnelius to the Board of Beactica Therapeutics," said Dr Per Källblad, CEO of Beactica Therapeutics. "His extensive experience in the corporate clinical development of life-changing oncology drugs will be valuable as Beactica accelerates its strategic plan to become a clinical-stage company." "We are delighted to welcome Jarl Ulf Jungnelius to the Board of Beactica Therapeutics," said DrPer Källblad, CEO of Beactica Therapeutics. "His extensive...

"We are delighted to welcome Jarl Ulf Jungnelius to the Board of Beactica Therapeutics," said Dr Per Källblad, CEO of Beactica Therapeutics. "His extensive experience in the corporate clinical development of life-changing oncology drugs will be valuable as Beactica accelerates its strategic plan to become a clinical-stage company."

About Beactica Therapeutics

Beactica Therapeutics AB is a privately held precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics with a focus to treat genetically defined cancers with significant unmet medical need. Beactica's approach is centered around targeting synthetically lethal disease proteins with allosteric modulators and targeted protein degraders. Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit www.beactica.com.  

Beactica Therapeutics Contact
Per Källblad M.Sc. Ph.D.
CEO
per.kallblad@beactica.com
Tel: +46 18 56 08 80

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/beactica-therapeutics-appoints-jarl-ulf-jungnelius-md-to-its-board-of-directors-as-it-advances-towards-clinical-stage-activities-301853971.html